AstraZeneca Pharmaceuticals LP Post Doc Fellow - Role of FGF21 in cardiac metabolism and mitochondrial function in Gothenburg, Sweden
At AstraZeneca, we believe in the potential of people who share our passion for science. By thinking boldly and working collaboratively to pursue discoveries beyond imagination, you’ll develop further and faster than you thought possible. We’ll complement your drive and determination to meet unmet patient needs around the world with the inspiration and opportunities to enhance your niche expertise and build your skills. So if you’re curious about what science can do, come and make a difference.
As a world leader in cardiovascular and metabolic medicines we are always working on innovative new drugs that will change lives across the globe. To make that happen, we have focused our small molecule research strategy in diabetes on islet health and downstream complications including diabetic kidney and liver disease. You will focus your efforts on making real progress toward slowing, stopping or curing some of the most aggressive diseases that face humanity today.
Main duties and responsibilities
This exciting opportunity within our Cardiovascular Innovative Medicine Unit focuses on exploring the role of fibroblast growth factor 21 (FGF21) in regulating cardiac metabolism, both in vitro and in vivo.
You’ll perform in vivo studies to explore the metabolic effects of FGF21 in mice and potential consequences on heart function in insulin sensitive and insulin resistant mice. Characterising mitochondrial function of cardiomyocytes isolated from insulin sensitive and insulin resistant mice will be a key part of your remit, as will dissecting regulatory role of FGF21 on mitochondrial respiration in cultured cardiomyocytes with or without induction of hypertrophy. We’ll expect you to communicate your results both within AstraZeneca via global working groups and externally at meetings and through publications.
You’ll work in an environment with extensive drug discovery with many experienced drug hunters at AstraZeneca, as well as with Professor Patrick Rensen from the Dept. Medicine, Div. Endocrinology at the Leiden University Medical Center (LUMC), who has great knowledge in lipid and glucose metabolism in relation to diabetes and cardiac disease.
PhD and/or MD in biomedical sciences or similar
Broad understanding of whole body energy metabolism
Licence to perform in vivo studies in rodents and skilled in performing studies on glucose and lipid metabolism
Initiative, motivation, and focus in developing ideas
Strong team player with excellent communication skills
Excellent oral and written presentation skills.
- Additional experience in cell biology and molecular biology
To apply for this position, please click the apply link below
AstraZeneca is an equal opportunity employer. AstraZeneca will consider all qualified applicants for employment without discrimination on grounds of disability, sex or sexual orientation, pregnancy or maternity leave status, race or national or ethnic origin, age, religion or belief, gender identity or re-assignment, marital or civil partnership status, protected veteran status (if applicable) or any other characteristic protected by law. AstraZeneca only employs individuals with the right to work in the country/ies where the role is advertised.
This is a 2-year, fixed-term contract based in Mölndal, Sweden, plus 1 year which will be merit based with a competitive salary on offer.
For further details about this opportunity, please contact Xiao-Rong.Peng@astrazeneca.com
Applications open: 17 February 2017
Applications close: 18 April 2017
If you share our passion for scientific excellence, find out more at careers.astrazeneca.com